Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA Advisory Panel Backs Approval Of Johnson & Johnson's Hepatitis C Drug-Reuters


Thursday, 24 Oct 2013 04:36pm EDT 

Reuters reported that an advisory committee of the U.S. Food and Drug Administration voted unanimously to approve Johnson & Johnson's hepatitis C drug. The panel voted 19-0 in favor of the drug, simeprevir, which was tested in combination with standard hepatitis C drugs, peginterferon-alpha and ribavirin. The drug is being developed by J&J unit Janssen Research & Development LLC. It is being tested in adults who failed previous interferon-based therapy or had not received medication at all. The FDA usually follows the recommendation of the advisory panel, although it is not obligated to do so. Hepatitis C, an infection of the liver transmitted through the blood, kills more than 15,000 Americans each year, mostly from hepatitis C-related illnesses such as cirrhosis and liver cancer. 

Company Quote

105.06
0.47 +0.45%
26 Dec 2014